Retinai, Swiss & US-based software company and founded in 2017 is among the few companies in the field of ophthalmology using artificial intelligence (AI) technologies.
Retinai offers a suite of AI-driven products designed to address various aspects of eye care. Ranging from diagnosis to Patient selection, and Tele-ophthalmology, Clinic management and even Precision Medicine.
RetinAI Discovery
Like RetinAI Discovery is a CE-Marked medical image and data management platform with certified AI Models to aggregate data and extracting automatic insights on patient diseases and outcomes. The platform can be configured to connect to PACS or integrate via API calls with the clinic systems.
Their products or Services for Clinical Care can be categorized into two major categories or fields.
Daily Clinical Workflow Solution
For daily clinical management in Opthalmology clinics, Retinai has introduced DIscovery For Clinics. Discovery® for Clinics uses AI models to enhance patient treatments & deliver the right treatment, at the point of care.
Currently Retinai’s platform is being used by two Swiss-based eye care centre networks Gutblick and Swiss Visio.
Retinai Disease Evaluation Apps for Clinics
These apps provide actionable insights and expert-level analysis, facilitating more accurate and timely management of different ocular pathological conditions.
Fluid Segmentation Model
The Fluid Segmentation Model is designed to identify and quantify the volume of different pathological fluids like intraretinal fluid (IRF), subretinal fluid (SRF), and pigment epithelium detachment (PED). Helping monitor conditions like AMD and diabetic macular edema (DME).
Layer Segmentation Model
The Layer Segmentation Model offers detailed measurements of retinal thickness across several key layers.
Macula Biomarkers Model
The Macula Biomarkers Model provides probability assessments of the presence or absence of specific retinal biomarkers within OCT volumes.
Geographic Atrophy (GA) Model
The Retinai’s GA Model specializes in segmenting geographic atrophy from OCT scans. It provides:
– GA segmentation on B-scans
– En-face GA segmentation in Localiser images
– En-face layer information for PR+RPE and CS+CC
– Calculation of affected GA area
– Progression prediction
Pricing
RetinAI’s Disease Evaluation Apps can be accessed on a usage-based pricing model. The pricing structure is designed to be cost-efficient ensuring that clinics only pay for what they use, making it budget friendly to integrate these advanced AI tools into the practices.
Each report for conditions such as nAMD, dAMD, DR/DME, and CME costs one credit, whereas a GA report requires three credits. If we talk about the price per credit, 100 credits are priced at €5 each, totaling €500, while 2,000 credits are priced at €2.50 each, totaling €5,000 instead of €10,000.
You can get 25 free credits to try out the apps by registering for Launch Offer.
Research and Clinical Validation
RetinAI’s AI models are built on real-world evidence and have been rigorously validated against expert graders, achieving similar performance levels. The CE-marked models are approved for clinical use in the European Union.
Recently, Ikerian (parent company of RetinAI U.S. Inc.) has received EU-MDR Certificate for four devices, its Ophthalmology Data Platform and AI models. The Retinai Discovery platform is cleared for clinical use by the FDA but the AI modules for biomarkers, fluid and layer segmentation and quantification in retinal pathologies are for research use only, in the USA.